期刊文献+

Clinical experience in the use of marginal donor hearts 被引量:2

Clinical experience in the use of marginal donor hearts
原文传递
导出
摘要 Background Although heart transplantation has become a standard therapy for end-stage heart disease, there are few published studies regarding the use of transplant organs from marginal donors. Here we describe the clinical outcome we have obtained using marginal donor hearts.Methods We analyzed 21 cases of orthotropic heart transplantation for end-stage heart disease performed in our department between September 2008 and July 2010. Of these patients, six received hearts from marginal donors and the remainder received standard-donor hearts. The two groups were compared in terms of both mortality and the incidence of perioperative complications such as infection, acute rejection, and right heart insufficiency.Results The 1-year survival rate of both groups was 100%. Only one death was recorded in standard-donor group during follow-up. Patients who received marginal donor hearts (83%) experienced more early complications than did the standard-donor-heart group (13%), but the mortality of the two groups was the same. The duration of post-ICU stay was greater in the marginal donor group than in the standard-donor group, (35.5±17.4) days and (21.7±2.6) days, respectively (P <0.05).Conclusions The use of marginal donor hearts increases the number of patients who can receive and benefit from transplants. However, it may introduce an increased risk of early complications, thus care should be taken both in the choice of patients who will receive marginal donor hearts and in the perioperative treatment of those for whom the procedure is performed. Background Although heart transplantation has become a standard therapy for end-stage heart disease, there are few published studies regarding the use of transplant organs from marginal donors. Here we describe the clinical outcome we have obtained using marginal donor hearts.Methods We analyzed 21 cases of orthotropic heart transplantation for end-stage heart disease performed in our department between September 2008 and July 2010. Of these patients, six received hearts from marginal donors and the remainder received standard-donor hearts. The two groups were compared in terms of both mortality and the incidence of perioperative complications such as infection, acute rejection, and right heart insufficiency.Results The 1-year survival rate of both groups was 100%. Only one death was recorded in standard-donor group during follow-up. Patients who received marginal donor hearts (83%) experienced more early complications than did the standard-donor-heart group (13%), but the mortality of the two groups was the same. The duration of post-ICU stay was greater in the marginal donor group than in the standard-donor group, (35.5±17.4) days and (21.7±2.6) days, respectively (P <0.05).Conclusions The use of marginal donor hearts increases the number of patients who can receive and benefit from transplants. However, it may introduce an increased risk of early complications, thus care should be taken both in the choice of patients who will receive marginal donor hearts and in the perioperative treatment of those for whom the procedure is performed.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2011年第8期1185-1188,共4页 中华医学杂志(英文版)
关键词 heart transplantation marginal donor heart COMPLICATION heart transplantation marginal donor heart complication
  • 相关文献

参考文献21

  • 1Copeland JG.Only optimal donors should be accepted for heart transplantation:protagonist.J Heart Lung Transplant 1995; 14 (6 Pt 1):1038-1042.
  • 2Wittwer T,Wahlers T.Marginal donor grafts in heart transplantation:lessons learned from 25 years of experience.Transpl Int 2008; 21:113-125.
  • 3Jeevanandam V,Furukawa S,Prendergast TW,Todd BA,Eisen HJ,McClurken JB.Standard criteria for an acceptable donor heart are restricting heart transplantation.Ann Thorac Surg 1996; 62:1268-1275.
  • 4Nagele H,Rodiger W.Sudden death and tailored medical therapy in elective candidates for heart transplantation.J Heart Lung Transplant 1999; 18:869-876.
  • 5Cooper DK,Keogh AM,Brink J,Conris PA,Klepetko W,Pierson RN,et al.Report of the Xenotransplantation Advisory Committee of the International Society for Heart and Lung Transplantation:the present status of xenotransplantation and its potential role in the treatment of end-stage cardiac and pulmonary diseases.J Heart Lung Transplant 2000; 19:1125-1165.
  • 6Felker GM,Milano CA,Yager JE,Hernandez AF,Blue L,Higginbotham MB,et al.Outcomes with an alternate list strategy for heart transplantation.J Heart Lung Transplant 2005; 24:1781-1786.
  • 7Chen JM,Russo M J,Hammond KM,Mancini DM,Kherani AR,Fal JM,et al.Alternate waiting list strategies for heart transplantation maximize donor organ utilization.Ann Thorac Surg 2005; 80:224-228.
  • 8Zaroff JG,Rosengard BR,Armstrong WF,Babcock WD,D'Alessandro A,Dec GW,et al.Consensus conference report:maximizing use of organs recovered from the cadaver donor:cardiac recommendations,March 28-29,2001,Crystal City,Va.Circulation 2002; 106:836-841.
  • 9Torres Macho J,Delgado Jimenez JF,Sanz Salvo J,Gonzalez Mansilla A,Sanchez Sanchez V,Gamez Diez S,et al.Effect of different pharmacologic agents to reverse severe pulmonary hypertension among end-stage heart failure patients.Transplant Proc 2009; 41:2477-2479.
  • 10Stewart S,Winters GL,Fishbein MC,Tazelaar HD,Kobashigawa J,Abrams J,et al.Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection.J Heart Lung Transplant 2005; 24:1710-1720.

同被引文献10

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部